CC-671

CC-671 is an orally bioavailable small molecule that acts as a dual inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps1) and CDC-like kinases (specifically CLK1 and CLK2). Developed by Celgene, it was designed to target the spindle assembly checkpoint and alternative mRNA splicing, two critical processes often dysregulated in malignant cells. By inhibiting TTK, CC-671 causes premature exit from mitosis, leading to chromosomal instability and cell death. Its inhibition of CLKs further disrupts the splicing of essential oncogenic transcripts. While it demonstrated potent preclinical activity in triple-negative breast cancer (TNBC) and was evaluated in Phase 1 clinical trials, its development was ultimately terminated following the acquisition of Celgene by Bristol Myers Squibb.